S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

LON:FARN - Faron Pharmaceuticals Oy Share Price, Forecast & News

GBX 280
+7.50 (+2.75 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
276
Now: GBX 280
298
50-Day Range
207.50
MA: GBX 246.29
277.50
52-Week Range
54.49
Now: GBX 280
320.50
Volume98,909 shs
Average Volume14,501 shs
Market Capitalization£121.21 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute organ traumas, vascular damage, and cancer immunotherapy. The company's lead product candidate is Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS). Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+358-2-4695151

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book ValueGBX 25.10 per share

Profitability

Miscellaneous

Employees18
Market Cap£121.21 million
Next Earnings DateN/A
OptionableNot Optionable

Receive FARN News and Ratings via Email

Sign-up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.


Faron Pharmaceuticals Oy (LON:FARN) Frequently Asked Questions

What is Faron Pharmaceuticals Oy's stock symbol?

Faron Pharmaceuticals Oy trades on the London Stock Exchange (LON) under the ticker symbol "FARN."

Has Faron Pharmaceuticals Oy been receiving favorable news coverage?

Media coverage about FARN stock has trended somewhat negative this week, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Faron Pharmaceuticals Oy earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Faron Pharmaceuticals Oy.

Who are some of Faron Pharmaceuticals Oy's key competitors?

What other stocks do shareholders of Faron Pharmaceuticals Oy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Faron Pharmaceuticals Oy investors own include Horizon Discovery Group (HZD), Celgene (CELG), Northwest Pipe (NWPX), TriQuint Semiconductor (TQNT), Acura Pharmaceuticals (ACUR), Bacanora Lithium (BCN), Angus Energy (ANGS), Allergy Therapeutics (AGY), Active Energy Group (AEG) and Namibian Resources (AAOG).

Who are Faron Pharmaceuticals Oy's key executives?

Faron Pharmaceuticals Oy's management team includes the folowing people:
  • Mr. Yrjö Erik Kristian Wichmann, CFO & Exec. Director (Age 61)
  • Dr. Juho Markku Jalkanen, Chief Devel. Officer (Age 41)
  • Dr. Markku Tapani Jalkanen Ph.D., Founder, CEO & Exec. Director (Age 64)
  • Dr. Mikael Maksimow Ph.D., VP of Operations (Age 43)
  • Dr. Matti Karvonen, Chief Medical Officer & VP of Drug Devel.

How do I buy shares of Faron Pharmaceuticals Oy?

Shares of FARN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Faron Pharmaceuticals Oy's stock price today?

One share of FARN stock can currently be purchased for approximately GBX 280.

How big of a company is Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy has a market capitalization of £121.21 million. Faron Pharmaceuticals Oy employs 18 workers across the globe.View Additional Information About Faron Pharmaceuticals Oy.

What is Faron Pharmaceuticals Oy's official website?

The official website for Faron Pharmaceuticals Oy is http://www.faron.com/.

How can I contact Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy's mailing address is Intelligate, Joukahaisenkatu 6, TURKU, 20520, Finland. The company can be reached via phone at +358-2-4695151.


MarketBeat Community Rating for Faron Pharmaceuticals Oy (LON FARN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  478
MarketBeat's community ratings are surveys of what our community members think about Faron Pharmaceuticals Oy and other stocks. Vote "Outperform" if you believe FARN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FARN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: Stocks at 52 Week High

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel